CompletedPhase 1NCT06863233

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells

Checked against the public recordLast updated Aug 26, 2026 · Source: ClinicalTrials.gov

StatusCompleted
PhasePhase 1
U.S. locations7
SponsorMemorial Sloan Kettering Cancer Center
01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Phase 1
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Drug: Zirconium Zr 89 crefmirlimab berdoxam; Diagnostic Test: PET/CT Scan
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Patient must be 18 years of age or older at the time of signing the informed consent. * Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer * Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet. * Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product. * Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Patient or legally authorized representative provided written authorization for use and disclosure of protected health information. Exclusion Criteria: * Pregnant or breastfeeding women * Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memorial Sloan Kettering at Basking Ridge (Consent Only)Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Consent Only)Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Consent Only)Montvale, New Jersey
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)Commack, New York
  • Memorial Sloan Kettering Westchester (Consent only)Harrison, New York
  • Memorial Sloan Kettering Cancer Center (All protocol activities)New York, New York
  • Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)Uniondale, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 26, 2026. Always confirm current availability with the study team.

View original record ↗